<DOC>
	<DOCNO>NCT00796068</DOCNO>
	<brief_summary>This phase II trial study well give treosulfan together fludarabine phosphate total-body irradiation ( TBI ) work treat patient hematological cancer undergo umbilical cord blood transplant ( UCBT ) . Giving chemotherapy , treosulfan fludarabine phosphate , TBI donor UCBT help stop growth cancer cell help stop patient 's immune system reject donor 's stem cell . When stem cell relate unrelated donor , exactly match patient 's blood , infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving cyclosporine mycophenolate mofetil transplant may stop happening .</brief_summary>
	<brief_title>Treosulfan , Fludarabine Phosphate , Total-Body Irradiation Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I. Graft failure/rejection secondary graft failure . II . Day -200 non-relapse mortality . SECONDARY OBJECTIVES : I. Platelet engraftment six month . II . Grade II-IV III-IV acute graft-versus-host disease ( GVHD ) day 100 one year . III . Chronic GVHD . IV . Clinically significant infection . V. Overall survival . VI . Relapse disease progression . VII . Immune reconstitution ( Fred Hutchinson Cancer Research Center [ FHCRC ] ) . VIII . Emergence dominant unit ( FHCRC ) . OUTLINE : ARM I ( low risk graft failure ) : Patients receive condition regimen comprise fludarabine phosphate intravenously ( IV ) 1 hour daily ( QD ) day -6 -2 treosulfan IV 120 minute day - 6 -4 . Patients undergo TBI day -1 . Patients undergo donor UCBT day 0 . Patients receive GVHD prophylaxis comprise cyclosporine IV orally ( PO ) 2-3 time daily day -3 100 , follow taper absence GVHD . Patients also receive mycophenolate mofetil IV 3 time daily day 0 40 , follow taper absence GVHD . ARM II ( high risk graft failure ) : Patients receive condition regimen , TBI , donor UCBT , GVHD prophylaxis , mycophenolate mofetil Arm I . After completion study treatment , patient follow 6 month 1 2 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Leukemia , Biphenotypic , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Treosulfan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Acute myeloid leukemia/acute lymphoblastic leukemia , include biphenotypic acute leukemia mixedlineage leukemia : Must &lt; 5 % morphologic marrow blast evaluable marrow sample ( &gt; 25 % normal cellularity age collect less one month prior start conditioning ; patient adequate marrow/biopsy specimen obtain determine remission status morphologic assessment , fulfil criterion remission flow cytometry , recovery peripheral blood count circulate blast , and/or normal cytogenetics ( applicable ) may still eligible ; reasonable attempt must make obtain adequate specimen morphologic assessment , include possible repeat procedure ; patient must discuss principal investigator prior enrollment ; patient persistently aplastic great one month since complete last chemotherapy also eligible Principal Investigator ( PI ) approval Myelodysplastic syndrome ( MDS ) : Any 2001 World Health Organization ( WHO ) classification subtype ; refractory anemia excess blast ( RAEB ) 2 patient may proceed directly transplant , may also consider induction chemotherapy transplant ; patient &gt; = 20 % morphologic marrow blast require induction therapy reduce morphologic marrow blast 5 % transplant Chronic myelogenous leukemia : All type , except refractory blast crisis ; chronic phase patient must fail intolerant Gleevec tyrosine kinase inhibitor Patients = &lt; 50 must performance status score : Karnofsky ( adult ) &gt; = 70 Eastern Cooperative Oncology Group ( ECOG ) 01 ; Lansky ( child ) score &gt; = 50 Patients &gt; 50 must Karnofsky performance score &gt; = 70 ECOG 01 comorbidity index &lt; 5 Adequate cardiac function define absence decompensated congestive heart failure uncontrolled arrhythmia AND leave ventricular ejection fraction &gt; = 35 % OR fractional shortening &gt; 22 % Adequate pulmonary function define absence oxygen ( O2 ) requirement one following : Diffusion lung capacity carbon monoxide ( DLCO ) correct &gt; = 70 % mm Hg DLCO correct 60 % 69 % mm Hg partial pressure oxygen ( pO2 ) &gt; = 70 mm Hg DLCO correct 50 % 59 % mm Hg pO2 &gt; = 80 mm Hg Adequate hepatic function ; patient clinical laboratory evidence liver disease evaluate cause liver disease , clinical severity term liver function , histology , degree portal hypertension ; patient fulminant liver failure , cirrhosis evidence portal hypertension bridge fibrosis , alcoholic hepatitis , esophageal varix , history bleed esophageal varix , hepatic encephalopathy , correctable hepatic synthetic dysfunction evidence prolongation prothrombin time , ascites related portal hypertension , bacterial fungal abscess , biliary obstruction , chronic viral hepatitis total serum bilirubin &gt; 3 mg/dL , symptomatic biliary disease exclude Adequate renal function define creatinine = &lt; 2.0 mg/dl ( adult ) creatinine clearance &gt; 40 ml/min ( pediatrics ) ; adult creatinine &gt; 1.2 history renal dysfunction must estimate creatinine clearance &gt; 40 ml/min If recent mold infection , e.g. , Aspergillus , must clear infectious disease proceed Prior hematopoietic cell transplant : must &gt; = 3 month previous transplant DONOR : Human leukocyte antigen ( HLA ) matching : Minimum requirement : The cord blood ( CB ) graft ( ) must match minimum 4/6 HLAA , B , DRB1 locus recipient ; therefore 02 mismatch A B DRB1 locus base intermediate resolution A , B antigen DRB1 allele type determination HLAmatch allow HLAmatching determine high resolution type allow per institutional guideline long minimum criterion ( ) meet DONOR : Selection two CB unit mandatory single cord blood unit meet follow criterion table Match grade 6/6 Single unit allow total nucleated cell ( TNC ) dose &gt; = 2.5 x 10^7/kg 5/6 , 4/6 Single unit allow TNC dose &gt; = 4.0 ( +/ 0.5 ) x 10^7/kg If two CB unit use , total cell dose combine unit must least 3.0 x 10^7 TNC per kilogram recipient weight base precryopreservation number , CB unit contain MINIMUM 1.5 x 10^7 TNC/kg Pregnancy breastfeed Evidence human immunodeficiency virus ( HIV ) infection know HIV positive serology Uncontrolled viral bacterial infection time study enrollment Active recent ( prior 6 month ) invasive fungal infection without infectious disease ( ID ) consult approval Central nervous system ( CNS ) leukemic involvement clear intrathecal chemotherapy and/or cranial radiation prior initiation conditioning ( day 6 ) DONOR : Any cord blood unit &lt; 1.5 x 10^7 total nucleated cell per kilogram recipient weight DONOR : Any cord blood unit without full maternal test negative result hepatitis A , B , C , HIV , human Tlymphotropic virus ( HTLV ) 1 virus ; additional available virology result unit review mandate , complete always available</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>